share_log

Additional Considerations Required While Assessing APT Medical's (SHSE:688617) Strong Earnings

Additional Considerations Required While Assessing APT Medical's (SHSE:688617) Strong Earnings

在评估APT Medical(SHSE: 688617)的强劲收益时需要考虑其他因素
Simply Wall St ·  03/31 20:30

APT Medical Inc. (SHSE:688617) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the numbers.

APT Medical Inc.(上海证券交易所股票代码:688617)宣布了丰厚的利润,但该股停滞不前。我们的分析表明,股东们注意到了一些令人担忧的数字。

earnings-and-revenue-history
SHSE:688617 Earnings and Revenue History April 1st 2024
SHSE: 688617 2024 年 4 月 1 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand APT Medical's profit results, we need to consider the CN¥45m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

为了正确理解APT Medical的利润业绩,我们需要考虑不寻常项目带来的4500万元人民币的收益。虽然获得更高的利润总是件好事,但来自不寻常物品的巨额捐款有时会抑制我们的热情。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。考虑到这个名字,这并不奇怪。假设这些不寻常的项目在本年度不会再次出现,因此我们预计明年的利润将疲软(也就是说,在业务没有增长的情况下)。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On APT Medical's Profit Performance

我们对APT Medical盈利表现的看法

We'd posit that APT Medical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that APT Medical's statutory profits are better than its underlying earnings power. But the good news is that its EPS growth over the last three years has been very impressive. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Ultimately, this article has formed an opinion based on historical data. However, it can also be great to think about what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here.

我们认为,APT Medical的法定收入并不能完全反映持续的生产力,这是因为这个很大的不寻常项目。因此,我们认为APT Medical的法定利润可能好于其基础盈利能力。但好消息是,其在过去三年中的每股收益增长非常令人印象深刻。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。最终,本文根据历史数据形成了观点。但是,考虑分析师对未来的预测也可能很好。在Simply Wall St,我们有分析师的估计,您可以点击此处查看。

Today we've zoomed in on a single data point to better understand the nature of APT Medical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单个数据点,以更好地了解APT Medical利润的性质。但是,还有很多其他方法可以让你对公司的看法。有些人认为高股本回报率是优质业务的好兆头。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发